OTCMKTS:MDGEF Medigene (MDGEF) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free MDGEF Stock Alerts $2.43 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$2.43▼$2.4350-Day Range$1.50▼$2.7652-Week Range$1.50▼$2.84VolumeN/AAverage Volume600 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartShort InterestStock AnalysisAnalyst ForecastsChartShort Interest Get Medigene alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About MedigeneMedigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.Read More MDGEF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGEF Stock News HeadlinesApril 26, 2024 | globenewswire.comMedigene AG reports Financial Results and Business Update for Q1 2024April 4, 2024 | globenewswire.comMedigene AG Secures European Patent for its iM-TCR TechnologyApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 28, 2024 | globenewswire.comMedigene AG Reports Full-Year 2023 Financial Results and Provides Corporate UpdateMarch 19, 2024 | globenewswire.comMedigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 18, 2024 | globenewswire.comMedigene AG to report full year 2023 financial results on March 28, 2024March 4, 2024 | globenewswire.comMedigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In VivoSee More Headlines Receive MDGEF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:MDGEF CUSIPN/A CIKN/A Webwww.medigene.com Phone(989) 200-0330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Selwyn Ho MB BS (Age 53)MBBS, CEO & Member of Executive Management Board Comp: $409.36kDr. Dolores J. SchendelChief Scientific Officer, Member of Executive Management Board and Head of Research & DevelopmentDr. Ernst-Ludwig Winnacker (Age 83)Co-Founder & Chairman Scientific Advisory Board Comp: $21.3kDr. Birger KohlertChief Financial OfficerPamela KeckVice President of Investor Relations & Corporate CommunicationsDr. Kirsty Crame M.D.VP and Head of Clinical Research & DevelopmentMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors MDGEF Stock Analysis - Frequently Asked Questions Should I buy or sell Medigene stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medigene in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDGEF shares. View MDGEF analyst ratings or view top-rated stocks. How have MDGEF shares performed in 2024? Medigene's stock was trading at $1.50 at the start of the year. Since then, MDGEF shares have increased by 62.0% and is now trading at $2.43. View the best growth stocks for 2024 here. Are investors shorting Medigene? Medigene saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 13,900 shares, an increase of 414.8% from the March 31st total of 2,700 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days. View Medigene's Short Interest. How do I buy shares of Medigene? Shares of MDGEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MDGEF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.